336 related articles for article (PubMed ID: 19957161)
41. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
Koehler JA; Baggio LL; Cao X; Abdulla T; Campbell JE; Secher T; Jelsing J; Larsen B; Drucker DJ
Diabetes; 2015 Mar; 64(3):1046-56. PubMed ID: 25277394
[TBL] [Abstract][Full Text] [Related]
42. Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.
Lee J; Koehler J; Yusta B; Bahrami J; Matthews D; Rafii M; Pencharz PB; Drucker DJ
Mol Metab; 2017 Mar; 6(3):245-255. PubMed ID: 28271031
[TBL] [Abstract][Full Text] [Related]
43. Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2.
Mulvihill EE
Curr Opin Lipidol; 2018 Apr; 29(2):95-103. PubMed ID: 29432213
[TBL] [Abstract][Full Text] [Related]
44. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566
[TBL] [Abstract][Full Text] [Related]
45. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
46. Glucagon-like peptide-2 regulates release of chylomicrons from the intestine.
Dash S; Xiao C; Morgantini C; Connelly PW; Patterson BW; Lewis GF
Gastroenterology; 2014 Dec; 147(6):1275-1284.e4. PubMed ID: 25173752
[TBL] [Abstract][Full Text] [Related]
47. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
48. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
Baggio LL; Kim JG; Drucker DJ
Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
[TBL] [Abstract][Full Text] [Related]
49. Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
Jessen L; Aulinger BA; Hassel JL; Roy KJ; Smith EP; Greer TM; Woods SC; Seeley RJ; D'Alessio DA
Endocrinology; 2012 Dec; 153(12):5735-45. PubMed ID: 23033273
[TBL] [Abstract][Full Text] [Related]
50. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
51. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
[TBL] [Abstract][Full Text] [Related]
53. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R.
Yusta B; Baggio LL; Koehler J; Holland D; Cao X; Pinnell LJ; Johnson-Henry KC; Yeung W; Surette MG; Bang KW; Sherman PM; Drucker DJ
Diabetes; 2015 Jul; 64(7):2537-49. PubMed ID: 25735732
[TBL] [Abstract][Full Text] [Related]
54. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Esser N; Barrow BM; Choung E; Shen NJ; Zraika S
Islets; 2018; 10(5):175-180. PubMed ID: 30142012
[TBL] [Abstract][Full Text] [Related]
55. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.
Yamada C; Yamada Y; Tsukiyama K; Yamada K; Udagawa N; Takahashi N; Tanaka K; Drucker DJ; Seino Y; Inagaki N
Endocrinology; 2008 Feb; 149(2):574-9. PubMed ID: 18039776
[TBL] [Abstract][Full Text] [Related]
56. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
[TBL] [Abstract][Full Text] [Related]
57. Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.
Yang Y; Tong Y; Gong M; Lu Y; Wang C; Zhou M; Yang Q; Mao T; Tong N
Cell Signal; 2014 Feb; 26(2):268-78. PubMed ID: 24269940
[TBL] [Abstract][Full Text] [Related]
58. Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury.
Han W; Li Y; Cheng J; Zhang J; Chen D; Fang M; Xiang G; Wu Y; Zhang H; Xu K; Wang H; Xie L; Xiao J
J Cell Mol Med; 2020 Aug; 24(15):8687-8702. PubMed ID: 32573108
[TBL] [Abstract][Full Text] [Related]
59. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
Gu W; Winters KA; Motani AS; Komorowski R; Zhang Y; Liu Q; Wu X; Rulifson IC; Sivits G; Graham M; Yan H; Wang P; Moore S; Meng T; Lindberg RA; Véniant MM
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E624-32. PubMed ID: 20647556
[TBL] [Abstract][Full Text] [Related]
60. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
